Advertisement
Advertisement
GILD
Gilead Sciences Inc
167.47
USDSponsored
-2.86
-1.68%
Nov 03, 16:00 UTC -5
Closed
Pre-Market
174.50
+7.03
+4.20%
Gilead Sciences Inc (GILD) Earnings
GILD Earnings Reports
Positive Surprise Ratio
GILD beat 28 of 43 last estimates.
65%
Next Report
Date of Next Report
Feb 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
$8.48B
/$1.48
Implied change from Q3 26 (Revenue/ EPS)
+2.16%
/-41.73%
Implied change from Q4 25 (Revenue/ EPS)
+6.99%
/-20.43%
Gilead Sciences Inc earnings per share and revenue
On Oct 29, 2026, GILD reported earnings of 2.54 USD per share (EPS) for Q3 26, beating the estimate of 2.23 USD, resulting in a 14.35% surprise. Revenue reached 8.30 billion, compared to an expected 7.97 billion, with a 4.20% difference. The market reacted with a +3.06% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 1.48 USD, with revenue projected to reach 8.48 billion USD, implying an decrease of -41.73% EPS, and increase of 2.16% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Royalty Pharma plc Class A Ordinary Shares
Report Date
Nov 04, 2026 For Q3 26
Estimate
$1.20
Actual
$1.21
Surprise
+0.39%
BioNTech SE - ADR
Report Date
Nov 03, 2026 For Q3 26
Estimate
$0.80
Actual
$1.81
Surprise
+126.53%
Rhythm Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+15.83%
Viridian Therapeutics, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.81
Surprise
+18.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$1.15
Actual
$0.81
Surprise
-30.03%
uniQure N.V.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.94
Actual
-$0.88
Surprise
+6.39%
Ultragenyx Pharmaceutical Inc.
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$1.13
Actual
-$1.15
Surprise
-1.83%
UroGen Pharma Ltd. Ordinary Shares
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.13
Actual
-$0.03
Surprise
-121.79%
Geron Corp
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.00
Actual
$0.00
Surprise
+100.00%
Nuvectis Pharma, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.24
Actual
-$1.02
Surprise
-313.79%
FAQ
What were Gilead Sciences Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Gilead Sciences Inc reported EPS of $2.54, beating estimates by 14.35%, and revenue of $8.30B, 4.2% above expectations.
How did the market react to Gilead Sciences Inc's Q3 2026 earnings?
The stock price moved up 3.06%, changed from $165.61 before the earnings release to $170.68 the day after.
When is Gilead Sciences Inc expected to report next?
The next earning report is scheduled for Feb 08, 2027.
What are the forecasts for Gilead Sciences Inc's next earnings report?
Based on --
analysts, Gilead Sciences Inc is expected to report EPS of $1.48 and revenue of $8.48B for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.